PACE-CME

The Physicians’ Academy for Cardiovascular Education aims to help physicians implement scientific findings in clinical practice, to improve patient outcome.

[Giuseppe Galati @GiuseppeGalati_]

🔥🔥🔥 #ESCPrev2025 Satellite symposium on “Novel Therapies for Managing Patients with #CardioKidneyMetabolic syndrome & #HeartFailure”

Together with @RInciardi & @cristina_gavina is now available for your view on @PACEcme

Do not miss it! : https://t.co/Y61XVfAcyT

@escardio

[Ankeet S. Bhatt, MD, MBA, ScM @ankeetbhatt]

Thanks @PACEcme for covering our #LBCT @escardio #HFA from #FINEARTSHF on the impact of randomization during/shortly post HF hosp on early HF readmission rates. Paper simpub in @JCardFail! Dedicated #REDEFINEHF trial underway to validate these findings.
https://t.co/gwQ6ouiiTQ

[PACE-CME @PACEcme]

Additional follow-up shows vutrisiran reduces mortality and CV event risks in ATTR-CM

Read more: https://t.co/xRSt2X1wxI

#HeartFailure2025 #ATTRCM #CardioTwitter

[PACE-CME @PACEcme]

Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?

@VarunSundaram4 shares the results of the PRAISE-HFrEF study. Watch: https://t.co/k9BXu6vHhG

#HeartFailure2025 #HFrEF #Obesity #PRAISEHFrEF #GLP1RA

[PACE-CME @PACEcme]

@mvaduganathan

Muthiah Vaduganathan shares the results of the blinded withdrawal of finerenone after long-term treatment in the FINEARTS-HF trial among patients with HFmrEF/HFpEF.

Learn more: https://t.co/qkI76DU03i

#HeartFailure2025 #HeartFailure #CardioTwitter

[Gianluigi Savarese @GianluSava]

Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes - great multidisciplinary discussion @PACEcme @HanCardiomd @_antocannata @MarcoMetra

https://t.co/eMWbpfqREO

[PACE-CME @PACEcme]

Echo essentials for HCM: The heartbeat of diagnosis and treatment

Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM

Learn more: https://t.co/t8GzqjGqRY

#HCM #cardiomyopathy

[PACE-CME @PACEcme]

Single LDL-c, hs-CRP, and Lp(a) measurement predicts long-term MACE risk in healthy Europeans

Read more: https://t.co/yJTPkUtxmN

#lipids #inflammation #CVD #CardioTwitter #CVrisk

[PACE-CME @PACEcme]

PACE-CME reports news from the ACC.25 Scientific Session. Follow our news coverage here: https://t.co/CW6JAkBaSO

#ACC25 #cardiology #cardiovascular #diabetes #CVD

[PACE-CME @PACEcme]

Icosapent ethyl in post-CABG patients with diabetes

Learn more: https://t.co/FDVlBNitY1

#cardiotwitter #icosapentethyl #CABG #diabetes

[PACE-CME @PACEcme]

Clinical choices in managing LDL-c: Where do novel therapies fit in?

Four experts discuss why LDL-c goal attainment is essential. Which options for LDL-c lowering are available, and where do novel therapies fit in?
Learn more: https://t.co/tkxnK5o6Vz

#lipids #CardioTwitter

[PACE-CME @PACEcme]

Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH

Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. Watch: https://t.co/dkEQmjx1TF

#CETP #lipids #FH #Obicetrapib #HeFH #AHA24 #BROOKLYN #CardioTwitter

[PACE-CME @PACEcme]

DOAC versus VKA after bioprosthetic valve replacement

Read more: https://t.co/FRLGSyb2YK

#AHA24 #CardioTwitter #Edoxaban #DOAC #VKA #ENBALV

[PACE-CME @PACEcme]

No effect of anticoagulation on cognitive decline in patients with AF at low risk of stroke

Read more: https://t.co/bERWQqk2Ry

#AHA24 #CardioTwitter #AF #Stroke #Cognitivedecline #BRAINAF

[PACE-CME @PACEcme]

Promising results with oral Lp(a) inhibitor in phase 2 trial

Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin was investigated in patients with elevated Lp(a) levels and high CV risk.

Watch: https://t.co/lWuwwI0j6r
#AHA24

[PACE-CME @PACEcme]

Tirzepatide reduces HF events in patients with HFpEF and obesity

“This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future”, says Milton Packer

Watch: https://t.co/T7q2YAlrKG

#AHA2024 #SUMMIT #HF

[PACE-CME @PACEcme]

Phase 3 study results of the APOC3 siRNA plozasiran in patients with familial chylomicronemia syndrome

Learn more: https://t.co/K45LUNNLne

#chylomicronemia #plozasiran #FCS #APOC3

[PACE-CME @PACEcme]

Optimizing care for patients with CKM syndrome: a multidisciplinary approach

Learn more: https://t.co/UQNQyGWVLQ

#CME #CardioTwitter #CKM #Cardiovascular #Kidney #Metabolic

[PACE-CME @PACEcme]

Lessons from global survey on Lp(a) levels in CHD

Read more: https://t.co/j5urXEwp77

#ESCCongress #Lpa #CardioTwitter #CHD #INTERASPIRE

[PACE-CME @PACEcme]

β-blocker therapy cannot be safely withdrawn in stable post-MI patients

Read more: https://t.co/LVfFsokrB7

#ESCCongress #ABYSS #postMI #betablocker #Cardiotwitter